KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.

This is the case, using an example relevant to the topic discussed in this review, for the addition of trametinib (a potent allosteric MEK inhibitor) to gemcitabine as first-line treatment of advanced PDAC patients [ 13 ]: while ineffective in the entire (unselected) trial population, it might have benefitted the small ( n = 40) population of KRAS wild type patients, in whom the risk of death was reduced by approximately 40% by the addition of trametinib, although with results that did not reach statistical significance [ 13 ].

also in 111,027 other papers